Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 253-261

  Ding, Xiaoling ^a   Zhou, Xiaorong ^a   Zhang, Haifeng ^a   Qing, Jingdan ^a   Qiang, Hui ^a   Zhou, Guoxiong ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

5 lipoxygenase; Pancreatic tumor; RNA interference; Triptolide; VEGF

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; SHORT HAIRPIN RNA; TRIPTOLIDE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; ARACHIDONATE 5-LIPOXYGENASE; CELL LINE, TUMOR; CELL PROLIFERATION; DITERPENES; EPOXY COMPOUNDS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PHENANTHRENES; RNA INTERFERENCE; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856762756     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1698-5     Document Type: Article

References (41)

1. M Hidalgo 2010 Pancreatic cancer N Engl J Med 362 1605 1617 20427809 10.1056/NEJMra0901557 1:CAS:528:DC%2BC3cXlsV2ns7o%3D
2. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 277 300 20610543 10.3322/caac.20073
3. A Maitra RH Hruban 2008 Pancreatic cancer Annu Rev Pathol 3 157 188 18039136 10.1146/annurev.pathmechdis.3.121806.154305 1:CAS:528: DC%2BD1cXjsFers7Y%3D (Pubitemid 351488279)
4. HH Wong NR Lemoine 2009 Pancreatic cancer: molecular pathogenesis and new therapeutic targets Nat Rev Gastroenterol Hepatol 6 412 422 19506583 10.1038/nrgastro.2009.89 1:CAS:528:DC%2BD1MXot12ltLo%3D
5. GX Zhou XL Ding JF Huang H Zhang SB Wu JP Cheng Q Wei 2008 Apoptosis of human pancreatic cancer cells induced by triptolide World J Gastroenterol 14 1504 1509 18330938 10.3748/wjg.14.1504 1:CAS:528:DC%2BD1cXkslKrtbg%3D (Pubitemid 351460162)
6. ZL Zhou ZG Luo B Yu Y Jiang Y Chen JM Feng M Dai LJ Tong Z Li YC Li J Ding ZH Miao 2010 Increased accumulation of hypoxia-inducible factor-1alpha with reduced transcriptional activity mediates the antitumor effect of triptolide Mol Cancer 9 268 20932347 10.1186/1476-4598-9-268
7. N Mujumdar TN Mackenzie V Dudeja R Chugh MB Antonoff D Borja-Cacho V Sangwan R Dawra SM Vickers AK Saluja 2010 Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways Gastroenterology 139 598 608 20434451 10.1053/j.gastro.2010.04.046 1:CAS:528:DC%2BC3cXpsVGms7c%3D
8. S Yang J Chen Z Guo XM Xu L Wang XF Pei J Yang CB Underhill L Zhang 2003 Triptolide inhibits the growth and metastasis of solid tumors Mol Cancer Ther 2 65 72 12533674 1:CAS:528:DC%2BD3sXhtlOit7w%3D
9. BZ Carter DH Mak WD Schober MF Dietrich C Pinilla LT Vassilev JC Reed M Andreeff 2008 Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5 Blood 111 3742 3750 18187663 10.1182/blood-2007-05-091504 1:CAS:528:DC%2BD1cXktlWmtrg%3D
10. WT Chang JJ Kang KY Lee K Wei E Anderson S Gotmare JA Ross GD Rosen 2001 Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway J Biol Chem 276 2221 2227 11053449 1:CAS:528:DC%2BD3MXotVCltw%3D%3D (Pubitemid 32109705)
11. A Comba ME Pasqualini 2009 Primers on molecular pathways-lipoxygenases: their role as an oncogenic pathway in pancreatic cancer Pancreatology 9 724 728 20016244 10.1159/000235623 1:CAS:528:DC%2BC3cXltVGjtLs%3D
12. WG Tong XZ Ding MS Talamonti RH Bell TE Adrian 2007 Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells Anticancer Drugs 18 535 541 17414622 10.1097/01.cad.0000231477.22901.8a 1:CAS:528:DC%2BD2sXjvVKiu70%3D (Pubitemid 46597408)
13. GP Pidgeon J Lysaght S Krishnamoorthy JV Reynolds K O'Byrne D Nie KV Honn 2007 Lipoxygenase metabolism: roles in tumor progression and survival Cancer Metast Rev 26 503 524 10.1007/s10555-007-9098-3 1:CAS:528:DC%2BD2sXht1yktLnO (Pubitemid 350115127)
14. R Hennig XZ Ding WG Tong MB Schneider J Standop H Friess MW Buchler PM Pour TE Adrian 2002 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue Am J Pathol 161 421 428 12163367 10.1016/S0002-9440(10)64198-3 1:CAS:528: DC%2BD38XntFektbg%3D (Pubitemid 36142151)
15. R Hennig P Grippo XZ Ding SM Rao MW Buchler H Friess MS Talamonti RH Bell TE Adrian 2005 5-Lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions Cancer Res 65 6011 6016 16024599 10.1158/0008-5472.CAN-04- 4090 1:CAS:528:DC%2BD2MXmt1eht7w%3D (Pubitemid 40994383)
16. YP Mao XL Tao PE Lipsky 2000 Analysis of the stability and degradation products of triptolide J Pharm Pharmacol 52 3 12 10716597 10.1211/ 0022357001773625 1:CAS:528:DC%2BD3cXhslKrt7w%3D (Pubitemid 30125277)
17. C Riccardi I Nicoletti 2006 Analysis of apoptosis by propidium iodide staining and flow cytometry Nat Protoc 1 1458 1461 17406435 10.1038/nprot.2006. 238 1:CAS:528:DC%2BD28Xht1eitL7K
18. M Cuendet JM Pezzuto 2000 The role of cyclooxygenase and lipoxygenase in cancer chemoprevention Drug Metabol Drug Interact 17 109 157 11201293 10.1515/DMDI.2000.17.1-4.109 1:CAS:528:DC%2BD3MXis1Ggug%3D%3D (Pubitemid 32049022)
19. ON Tucker AJ Dannenberg EK Yang F Zhang L Teng JM Daly RA Soslow JL Masferrer BM Woerner AT Koki TJ Fahey 3rd 1999 Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer Cancer Res 59 987 990 10070951 1:CAS:528:DyaK1MXhslemtLw%3D (Pubitemid 29135954)
20. S Grosch I Tegeder E Niederberger L Brautigam G Geisslinger 2001 COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib FASEB J 15 2742 2744 11606477 1:STN:280:DC%2BD3MnotVeksg%3D%3D
21. MI Patel K Subbaramaiah B Du M Chang P Yang RA Newman C Cordon-Cardo HT Thaler AJ Dannenberg 2005 Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism Clin Cancer Res 11 1999 2007 15756026 10.1158/1078-0432.CCR-04-1877 1:CAS:528:DC%2BD2MXitVKrsbg%3D (Pubitemid 40471866)
22. D Dhawan AB Jeffreys R Zheng JC Stewart DW Knapp 2008 Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells Mol Cancer Ther 7 897 904 18413803 10.1158/1535-7163.MCT- 07-0313 1:CAS:528:DC%2BD1cXks1GmsLk%3D (Pubitemid 351551043)
23. A Jimeno ML Amador P Kulesza X Wang B Rubio-Viqueira X Zhang A Chan J Wheelhouse H Kuramochi K Tanaka K Danenberg WA Messersmith V Almuete RH Hruban A Maitra CJ Yeo M Hidalgo 2006 Assessment of celecoxib pharmacodynamics in pancreatic cancer Mol Cancer Ther 5 3240 3247 17172427 10.1158/1535-7163.MCT-06- 0565 1:CAS:528:DC%2BD28XhtlagsbjO (Pubitemid 46092067)
24. LG Melstrom DJ Bentrem MR Salabat TJ Kennedy XZ Ding M Strouch SM Rao RC Witt CA Ternent MS Talamonti RH Bell TA Adrian 2008 Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model Clin Cancer Res 14 6525 6530 18927292 10.1158/1078-0432.CCR-07-4631 1:CAS:528:DC%2BD1cXht1KgtbnF
25. M Matsuyama R Yoshimura M Mitsuhashi K Tsuchida Y Takemoto Y Kawahito H Sano T Nakatani 2005 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway Oncol Rep 14 73 79 15944770 1:CAS:528:DC%2BD2MXmt1Chtb0%3D
26. R Yoshimura M Matsuyama K Tsuchida Y Kawahito H Sano T Nakatani 2003 Expression of lipoxygenase in human bladder carcinoma and growth inhibition by its inhibitors J Urol 170 1994 1999 14532840 10.1097/01.ju.0000080296.54262.c8 1:CAS:528:DC%2BD3sXnvV2it7g%3D (Pubitemid 37254995)
27. G Furstenberger P Krieg K Muller-Decker AJ Habenicht 2006 What are cyclooxygenases and lipoxygenases doing in the driver's seat of carcinogenesis? Int J Cancer 119 2247 2254 16921484 10.1002/ijc.22153 1:STN:280: DC%2BD28rotFGktg%3D%3D (Pubitemid 44546942)
28. AS Fischer J Metzner SD Steinbrink S Ulrich C Angioni G Geisslinger D Steinhilber TJ Maier 2010 5-Lipoxygenase inhibitors induce potent anti-proliferative and cytotoxic effects in human tumour cells independently of suppression of 5-lipoxygenase activity Br J Pharmacol 161 936 949 20860670 10.1111/j.1476-5381.2010.00915.x 1:CAS:528:DC%2BC3cXht1Kju7zJ
29. P Page LX Yang 2010 Novel chemoradiosensitizers for cancer therapy Anticancer Res 30 3675 3682 20944153 1:CAS:528:DC%2BC3cXhtlGksbfO
30. S Lev-Ari L Strier D Kazanov L Madar-Shapiro H Dvory-Sobol I Pinchuk B Marian D Lichtenberg N Arber 2005 Celecoxib and curcumin synergistically inhibit the growth of colorectal cancer cells Clin Cancer Res 11 6738 6744 16166455 10.1158/1078-0432.CCR-05-0171 1:CAS:528:DC%2BD2MXhtVShsb3J (Pubitemid 41339017)
31. W Wang S Yang Y Su Z Xiao C Wang X Li L Lin BM Fenton SF Paoni I Ding P Keng P Okunieff L Zhang 2007 Enhanced antitumor effect of combined triptolide and ionizing radiation Clin Cancer Res 13 4891 4899 17699869 10.1158/1078-0432.CCR-07-0416 1:CAS:528:DC%2BD2sXptVGmtLo%3D (Pubitemid 47294797)
32. JM Fidler K Li C Chung K Wei JA Ross M Gao GD Rosen 2003 PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy Mol Cancer Ther 2 855 862 14555704 1:CAS:528:DC%2BD3sXotVShtLs%3D
33. GX Zhou XL Ding JF Huang H Zhang SB Wu 2007 Suppression of 5-lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor cell lines Biochim Biophys Acta 1770 1021 1027 17434678 10.1016/j.bbagen.2007.03.002 1:CAS:528:DC%2BD2sXkvF2jtr8%3D (Pubitemid 46678610)
34. MF He YH Huang LW Wu W Ge PC Shaw PP But 2010 Triptolide functions as a potent angiogenesis inhibitor Int J Cancer 126 266 278 19569053 10.1002/ijc.24694 1:CAS:528:DC%2BD1MXhsVamtL7J
35. LA Shamon JM Pezzuto JM Graves RR Mehta S Wangcharoentrakul R Sangsuwan S Chaichana P Tuchinda P Cleason V Reutrakul 1997 Evaluation of the mutagenic, cytotoxic, and antitumor potential of triptolide, a highly oxygenated diterpene isolated from Tripterygium wilfordii Cancer Lett 112 113 117 9029176 10.1016/S0304-3835(96)04554-5 (Pubitemid 27067433)
36. JJ Kitzen MJ de Jonge CH Lamers FA Eskens D van der Biessen L van Doorn J Ter Steeg M Brandely C Puozzo J Verweij 2009 Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours Eur J Cancer 45 1764 1772 19251409 10.1016/j.ejca.2009.01.026 1:CAS:528: DC%2BD1MXnsV2lu7o%3D
37. K Tiemann JJ Rossi 2009 RNAi-based therapeutics-current status, challenges and prospects EMBO Mol Med 1 142 151 20049714 10.1002/emmm.200900023 1:CAS:528:DC%2BD1MXhtVWrurfO
38. L Aagaard JJ Rossi 2007 RNAi therapeutics: principles, prospects and challenges Adv Drug Deliv Rev 59 75 86 17449137 10.1016/j.addr.2007.03.005 1:CAS:528:DC%2BD2sXlvVOhtLw%3D (Pubitemid 46770900)
39. DH Kim JJ Rossi 2007 Strategies for silencing human disease using RNA interference Nat Rev Genet 8 173 184 17304245 10.1038/nrg2006 1:CAS:528:DC%2BD2sXhslOgtrw%3D
40. J De Vincenzo R Lambkin-Williams T Wilkinson J Cehelsky S Nochur E Walsh R Meyers J Gollob A Vaishnaw 2010 A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus Proc Natl Acad Sci USA 107 8800 8805 10.1073/pnas.0912186107
41. Hickerson RP, Leachman SA, Pho LN, Gonzalez-Gonzalez E, Smith FJ, McLean WH, Contag CH, Leake D, Milstone LM, Kaspar RL (2011) Development of quantitative molecular clinical end points for siRNA clinical trials. J Invest Dermatol 131:1029-1036